SightfileU.S. market data from official filings

SHATTUCK LABS INC (STTK)

Name: SHATTUCK LABS INC (STTK) — Institutional ownership, SEC filings and insider activity
Creator: Sightfile
License: https://www.sec.gov/privacy#dissemination

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001680367 · EDGAR filings · Updated 2026-07-17

SHATTUCK LABS INC (STTK) has reported institutional ownership of 73.1%, with 84 institutional managers holding positions valued at $360.4M per the latest 13F reporting period.

Institutional ownership

73.1%

Institutional managers

Reported 13F value

$360.4M

Insider activity

17 trans.

$11.0M net buying

Latest updates

2026-07-17 — SCHEDULE 13D/A filed
2026-07-07 — Insider transaction reported (Form 4)
2026-07-02 — Insider transaction reported (Form 4)
2026-07-02 — Insider transaction reported (Form 4)
2026-07-02 — Notice of proposed sale filed (Form 144)
2026-07-01 — Notice of proposed sale filed (Form 144)

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, SHATTUCK LABS INC has 84 institutional holders and institutional ownership of 73.1%.

Insider activity

Insiders reported 17 transactions (4 buys, 0 sells) across 9 reporting insiders, with a net reported value of $11.0M.

Related companies

X4 PHARMACEUTICALS INC (XFOR) · CYTEK BIOSCIENCES INC (CTKB) · NATURES SUNSHINE PRODS INC (NATR) · EMERGENT BIOSOLUTIONS INC (EBS) · ANTERIS TECHNOLOGIES GLOBAL (AVR) · REGENXBIO INC (RGNX)

See full history, cross-references and alerts on Sightfile

Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-17.